Press release
IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market
As per Persistence Market Research’s latest industry analysis, the global fibromyalgia antidepressants market was valued at US$ 440.8 Mn in 2020, and is expected to exhibit a healthy CAGR of 8.1% over the forecast period (2021-2031)
Rising prevalence of fibromyalgia caused due chronic back pain, previously associated spinal injury, trauma, osteoarthritis, road accidents, and musculoskeletal disorders are expected to drive demand for better treatment along with effective medications for fibromyalgia. Thus, demand for improved treatment with fibromyalgia antidepressants is expected to provide a positive impetus to market growth.
Treatment cost with branded drugs is significantly higher, and it is expected to remain high when compared with generic drugs or other off-label drugs. These higher costs will drive demand for generic drugs. The generic versions of these drugs are likely to see high demand in low-income economies or in economies where these products are limited or not available.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32898
Consolidation activities, mergers, and acquisitions have emerged as a key growth strategy among industry leaders. This trend is quite evident in key markets for fibromyalgia antidepressants.
For instance, the recent acquisition of Allergan plc by AbbVie Inc. in May 2020. This acquisition enabled AbbVie to strengthen its presence across key therapy areas, including immunology, hematologic oncology, and neuroscience.
Similarly, in June 2019, Eli Lily received FDA approval for its migraine drug Emgality, for its use in the treatment in management of cluster headaches.
Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com
Company Profiles:
Pfizer, Inc.
Eli Lilly and Company.
AbbVie, Inc
TONIX Pharmaceuticals Holdings Corp
Virios Therapeutics, Inc.
Aptinyx Inc.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32898
Key Takeaways from Market Study
In terms of drug class, duloxetine HCL drug holds around 57.8% market value share. Growth is primarily attributed as duloxetine HCL mainly used to treat patients with diabetes and long-term chronic pain.
Based on distribution channel, hospitals pharmacies are leading with over 46% market share, as more patients are consulted at hospitals for fibromyalgia.
By region, North America is set dominate the global market with a value share of around 45.8% in 2021. Europe is slated to be the second-largest leading regional market with a value share of around 20.5% in 2021.
“Rising number of cases of fibromyalgia and better availability of fibromyalgia antidepressant medication are expected to drive market growth over the coming years,” says an analyst of Persistence Market Research.
Market Competition
New product launches and approvals, agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
In January 2021, Eli Lilly acquired pharmaceutical rights from Aashi Kahei Pharma of its experimental drug in early-stage testing for managing chronic pain.
In October 2020, Eli Lily entered into a collaboration agreement with Daichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody, which has potential use in the treatment of migrane.
In July 2019, FSD BioSciences, Inc. acquired a U.S.-based company Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32898
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia anti-depressants market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on the drug class (venlafaxine, duloxetine HCL, milnacipran HCL, and others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online sales), and seven key regions of the world.
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/fibromyalgia-antidepressants-market.asp
Read More Trending "PMR Exclusive Article"-
Immune Repertoire Sequencing Market@ https://www.persistencemarketresearch.com/market-research/immune-repertoire-sequencing-market.asp
Life Science Market@ https://www.persistencemarketresearch.com/market-research/life-science-market.asp
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IoMT (Internet of Medical Things) to drive the Fibromyalgia Antidepressants Market here
News-ID: 2545474 • Views: …
More Releases from Persistence Market Research
Mobile Explosive Manufacturing Unit Market Poised to Surge to US$ 579 Million by …
Overview of the Mobile Explosive Manufacturing Unit Market
The global Mobile Explosive Manufacturing Unit (MEMU) market is witnessing steady growth driven by the rising demand for efficient and flexible explosive manufacturing solutions in the mining, construction, and quarrying sectors. Valued at approximately US$ 347.8 million in 2021, the market is forecasted to reach around US$ 579 million by 2031, registering a compound annual growth rate (CAGR) of 5.2% over the forecast…
Structured Content and Product Label Management Market Poised for Explosive Grow …
Overview of the Market
The Structured Content and Product Label Management Market is witnessing robust growth globally, driven by the increasing demand for streamlined content management and accurate product labeling across industries such as retail, pharmaceuticals, food and beverage, and manufacturing. Structured content refers to organizing information in a standardized, reusable format, facilitating efficient management, distribution, and compliance. Product label management is integral to regulatory adherence, consumer safety, and brand transparency,…
Personal Cooling Device Market Poised to Surge to US$ 9 Billion by 2033 - Insigh …
The global personal cooling device market is on a robust growth trajectory, anticipated to reach a market valuation of approximately US$ 9 billion by 2033. According to Persistence Market Research (PMR), the market size was estimated at US$ 6 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.1% between 2023 and 2033. This steady growth reflects increasing consumer demand for compact, wearable,…
Large Bore Vacuum Insulated Pipe Market Projected to Expand at a 7.6% CAGR Throu …
Overview of the Market
The Large Bore Vacuum Insulated Pipe (LBVIP) Market is a niche yet crucial segment in the infrastructure supporting cryogenic liquid transport. This specialized piping system is engineered to convey supercooled liquids such as liquid oxygen, liquid nitrogen, and liquid helium, with minimal thermal loss. Its design employs a dual stainless-steel pipe structure separated by a vacuum layer and super insulation to drastically reduce heat transfer, maintaining cryogenic…
More Releases for Fibromyalgia
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required…
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues. Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
Fibromyalgia can be diagnosed if the patient had widespread pain…
Fibromyalgia Treatment Ingredient Market | 2021 Trends, Size, Share
The global fibromyalgia treatment market size is expected to reach USD 1,414.4 million by 2027, exhibiting a CAGR of 9.2% during the forecast period. Fibromyalgia Treatment Ingredient Industry is segmentedBy Product Type (Single Energy Mode, Dual Energy Mode), By Vehicle Type (Passenger Cars, Commercial Vehicles) and regional forecast 2021-2027
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/fibromyalgia-treatment-market-105016
Strong Pipeline Products to Augment Growth
The prominent companies are focused on introducing innovative therapies…
Fibromyalgia Treatment Market Global Industry Insights 2018-2026
Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue and localized tenderness affecting individuals mentally, physically and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration and depression. Fibromyalgia symptoms…
Anticonvulsant Market for Fibromyalgia Optimistic Opportunities 2025
Anticonvulsant Market for Fibromyalgia: Snapshot
Anticonvulsants are pharmacological agents from a diverse group that are used for the treatment of epileptic seizures. Anticonvulsants are increasingly in demand on account of their use for the treatment of bipolar disorders. They are also used for the treatment of borderline personality disorder. Anticonvulsants act as stabilizers of mood and helps in the treatment of neuropathic pain. They suppress the rapid, excessive firing of neurons…
Chinese Fibromyalgia Market Research Report- Forecast to 2022
Market Scenario:
Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart…
